<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Peginterferon alfa-2a</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00008</strong>&#160; (BIOD00043, BTD00043)</td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Human interferon 2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched bis-monomethoxy polyethylene glycol (<span class="caps">PEG</span>) chain. The <span class="caps">PEG</span> moiety is linked at a single site to the interferon alfa moiety via a stable amide bond to lysine. Peginterferon alfa-2a has an approximate molecular weight of 60,000 daltons. Interferon alfa-2a is produced using recombinant <span class="caps">DNA</span> technology in which a cloned human leukocyte interferon gene is inserted into and expressed in Escherichia coli. The resultant protein is 165 amino acids. The <span class="caps">PEG</span> strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.</p></td></tr><tr><th>Protein structure</th><td><a href="/system/protein_structures/full/DB00008.png?1266600383"><img alt="Db00008" src="/system/protein_structures/thumb/DB00008.png?1266600383"></a></td></tr><tr><th>Protein chemical formula</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein average weight</th><td>60000.0000</td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;Peginterferon alfa-2a sequence
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB00008/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Pegasys</td><td>Hoffman-La Roche Inc</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/immunosuppressive-agents">Immunosuppressive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>198153-51-4</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.</td></tr><tr><th>Pharmacodynamics</th><td>Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.</td></tr><tr><th>Mechanism of action</th><td>Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>Terminal half life is 80 hours (range 50 to 140 hours).</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.roche.com">F Hoffmann La Roche Ltd.</a></li>
<li><a href="http://www.roche.com">F Hoffmann-La Roche Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Subcutaneous</td><td></td></tr></tbody></table></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Interferon increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB00651">Dyphylline</a></td><td>Interferon increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Etravirine (a CYP2C9 substrate), when used concomitantly with peginterferon alfa-2a, may experience a decrease in serum concentration. It is recommended to monitor effectiveness of etravirine therapy.</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Interferon increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB01265">Telbivudine</a></td><td>Co-administration of Peginterferon alpha-2a and Telbivudine may increase the risk of serious peripheral neuropathy.</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Interferon increases the effect and toxicity of theophylline</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Recommended adequate hydration.</li></ul></td></tr></tbody></table>